Melosky B - Search Results

1

Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non-small cell lung cancer.

Melosky B, Vincent MD, McGuire AL, Brade AM, Chu Q, Cheema P, Martins I, Spicer JD, Snow S, Juergens RA. Melosky B, et al. Int J Cancer. 2024 Sep 15;155(6):963-978. doi: 10.1002/ijc.35031. Epub 2024 Jun 20. Int J Cancer. 2024. PMID: 38900018 Review.

2

Colonic carcinoma in two adult cystic fibrosis patients.

Chaun H, Paty B, Nakielna EM, Schmidt N, Holden JK, Melosky B. Chaun H, et al. Among authors: melosky b. Can J Gastroenterol. 1996 Nov-Dec;10(7):440-2. doi: 10.1155/1996/372704. Can J Gastroenterol. 1996. PMID: 9113885

3

Less toxic chemotherapy improves uptake of all lines of chemotherapy in advanced non-small-cell lung cancer: a 10-year retrospective population-based review.

Ho C, Ramsden K, Zhai Y, Murray N, Sun S, Melosky B, Laskin J. Ho C, et al. Among authors: melosky b. J Thorac Oncol. 2014 Aug;9(8):1180-6. doi: 10.1097/JTO.0000000000000225. J Thorac Oncol. 2014. PMID: 25157771 Free article.

4

Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer.

Melosky B, Anderson H, Burkes RL, Chu Q, Hao D, Ho V, Ho C, Lam W, Lee CW, Leighl NB, Murray N, Sun S, Winston R, Laskin JJ. Melosky B, et al. J Clin Oncol. 2016 Mar 10;34(8):810-5. doi: 10.1200/JCO.2015.62.3918. Epub 2015 Nov 16. J Clin Oncol. 2016. PMID: 26573073 Clinical Trial.

5

Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition.

Melosky B, Chu Q, Juergens R, Leighl N, McLeod D, Hirsh V. Melosky B, et al. J Clin Oncol. 2016 May 10;34(14):1676-88. doi: 10.1200/JCO.2015.63.8049. Epub 2016 Feb 16. J Clin Oncol. 2016. PMID: 26884577 Review.

6

Shifting the paradigm for maintenance therapy in advanced non-small-cell lung cancer.

Melosky B. Melosky B. Lung Cancer (Auckl). 2010 Jun 5;1:53-62. doi: 10.2147/lctt.s5909. eCollection 2010. Lung Cancer (Auckl). 2010. PMID: 28210106 Free PMC article. Review.

7

Brigatinib is another treatment option for patients diagnosed with advanced ALK-positive non-small-cell lung cancer who are treatment-naïve or who have progressed on or are intolerant to crizotinib.

Melosky B, Cheema P, Liu G. Melosky B, et al. Curr Oncol. 2019 Feb;26(1):e119-e120. doi: 10.3747/co.26.4809. Epub 2019 Feb 1. Curr Oncol. 2019. PMID: 30853819 Free PMC article. No abstract available.

8

Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.

Melosky B, Juergens R, Hirsh V, McLeod D, Leighl N, Tsao MS, Card PB, Chu Q. Melosky B, et al. Oncologist. 2020 Jan;25(1):64-77. doi: 10.1634/theoncologist.2019-0027. Epub 2019 May 28. Oncologist. 2020. PMID: 31138727 Free PMC article. Clinical Trial.

9

Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.

Melosky B, Juergens R, McLeod D, Leighl N, Brade A, Card PB, Chu Q. Melosky B, et al. Lung Cancer. 2019 Aug;134:259-267. doi: 10.1016/j.lungcan.2019.05.027. Epub 2019 May 29. Lung Cancer. 2019. PMID: 31319991 Review.

10

Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model.

Moldaver D, Hurry M, Evans WK, Cheema PK, Sangha R, Burkes R, Melosky B, Tran D, Boehm D, Venkatesh J, Walisser S, Orava E, Grima D. Moldaver D, et al. Among authors: melosky b. Lung Cancer. 2020 Jan;139:185-194. doi: 10.1016/j.lungcan.2019.10.019. Epub 2019 Oct 22. Lung Cancer. 2020. PMID: 31812889 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

120 results

Search Page

Filters